John H. Rutherford sold GlaxoSmithKline PLC ADR (NYSE: GSK)
John H. Rutherford (R-FL), a U.S. Representative, has disclosed 1 trade in GlaxoSmithKline PLC ADR (GSK) since 2022, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: John H. Rutherford sold $1,001 - $15,000 of GlaxoSmithKline PLC ADR (NYSE: GSK) on February 17, 2022. Since that trade, GSK is up +47.23% against the S&P 500 up +76.93%, an outperformance of -29.70%.
Data updated
John H. Rutherford's GSK trades vs the price
GSK is up +47.23% since John H. Rutherford sold on February 17, 2022, versus +76.93% for the S&P 500.
Performance since this trade
All John H. Rutherford GSK trades
John H. Rutherford & GSK trading FAQ
Is it legal for John H. Rutherford to trade GlaxoSmithKline PLC ADR (GSK) stock?
Yes. Members of Congress are allowed to trade individual stocks, including GlaxoSmithKline PLC ADR (GSK), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did John H. Rutherford sell GSK?
John H. Rutherford disclosed a sale of $1,001 - $15,000 of GlaxoSmithKline PLC ADR (GSK) on February 17, 2022, according to public STOCK Act filings.
How has GSK performed since John H. Rutherford's trade?
Since John H. Rutherford sold GSK on February 17, 2022, the stock is up +47.23%, versus +76.93% for the S&P 500 over the same period, an outperformance of -29.70%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional GSK trades?
Quantellect tracks every disclosed congressional trade in GlaxoSmithKline PLC ADR (GSK) on the GlaxoSmithKline PLC ADR congressional trading page, which aggregates filings across all members of Congress.
John H. Rutherford's GSK tradesAll congressional filings for GlaxoSmithKline PLC ADRJohn H. Rutherford's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.